{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T22:36:34Z","timestamp":1794263794083,"version":"4.9.0"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T00:00:00Z","timestamp":1626134400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T00:00:00Z","timestamp":1626134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No.81970085"],"award-info":[{"award-number":["No.81970085"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No.81670086"],"award-info":[{"award-number":["No.81670086"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019065","name":"Tianjin Science and Technology Plan Project","doi-asserted-by":"crossref","award":["No. 17ZXMFSY00080"],"award-info":[{"award-number":["No. 17ZXMFSY00080"]}],"id":[{"id":"10.13039\/501100019065","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hypoxia is a pathological condition common to many diseases, although multiple organ injuries induced by hypoxia are often overlooked. There is increasing evidence to suggest that the hypoxic environment may activate innate immune cells and suppress adaptive immunity, further stimulating inflammation and inhibiting immunosurveillance. We found that dysfunctional immune regulation may aggravate hypoxia-induced tissue damage and contribute to secondary injury. Among the diverse mechanisms of hypoxia-induced immune dysfunction identified to date, the role of programmed death-ligand 1 (PD-L1) has recently attracted much attention. Besides leading to tumour immune evasion, PD-L1 has also been found to participate in the progression of the immune dysfunction which mediates hypoxia-induced multiple organ injury. In this review, we aimed to summarise the role of immune dysfunction in hypoxia-induced multiple organ injury, the effects of hypoxia on the cellular expression of PD-L1, and the effects of upregulated PD-L1 expression on immune regulation. Furthermore, we summarise the latest information pertaining to the involvement, diagnostic value, and therapeutic potential of immunosuppression induced by PD-L1 in various types of hypoxia-related diseases, including cancers, ischemic stroke, acute kidney injury, and obstructive sleep apnoea.<\/jats:p>","DOI":"10.1186\/s12964-021-00742-x","type":"journal-article","created":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T11:10:29Z","timestamp":1626174629000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["The role of PD-L1 in the immune dysfunction that mediates hypoxia-induced multiple organ injury"],"prefix":"10.1186","volume":"19","author":[{"given":"Yang","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyang","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5686-9253","authenticated-orcid":false,"given":"Qiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,13]]},"reference":[{"key":"742_CR1","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1159\/000496047","volume":"51","author":"S Song","year":"2018","unstructured":"Song S, Tan J, Miao Y, Sun Z, Zhang Q. Intermittent-hypoxia-induced autophagy activation through the ER-stress-related PERK\/eIF2alpha\/ATF4 pathway is a protective response to pancreatic beta-cell apoptosis. Cell Physiol Biochem. 2018;51:2955\u201371.","journal-title":"Cell Physiol Biochem"},{"key":"742_CR2","first-page":"1184","volume":"11","author":"P Duan","year":"2019","unstructured":"Duan P, Tan J, Miao Y, Zhang Q. Potential role of exosomes in the pathophysiology, diagnosis, and treatment of hypoxic diseases. Am J Transl Res. 2019;11:1184\u2013201.","journal-title":"Am J Transl Res"},{"key":"742_CR3","doi-asserted-by":"crossref","unstructured":"Guo Y, Tan J, Miao Y, Sun Z, Zhang Q: Effects of microvesicles on cell apoptosis under hypoxia. Oxid Med Cell Longev. 2019:5972152.","DOI":"10.1155\/2019\/5972152"},{"key":"742_CR4","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1038\/nri.2017.103","volume":"17","author":"CT Taylor","year":"2017","unstructured":"Taylor CT, Colgan SP. Regulation of immunity and inflammation by hypoxia in immunological niches. Nat Rev Immunol. 2017;17:774\u201385.","journal-title":"Nat Rev Immunol"},{"key":"742_CR5","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1056\/NEJMra0910283","volume":"364","author":"HK Eltzschig","year":"2011","unstructured":"Eltzschig HK, Carmeliet P. Hypoxia and inflammation. N Engl J Med. 2011;364:656\u201365.","journal-title":"N Engl J Med"},{"key":"742_CR6","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","volume":"11","author":"Y Ishida","year":"1992","unstructured":"Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. Embo J. 1992;11:3887\u201395.","journal-title":"Embo J"},{"key":"742_CR7","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/j.1600-065X.2010.00923.x","volume":"236","author":"LM Francisco","year":"2010","unstructured":"Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010;236:219\u201342.","journal-title":"Immunol Rev"},{"key":"742_CR8","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1182\/blood-2016-09-741629","volume":"129","author":"T Asano","year":"2017","unstructured":"Asano T, Meguri Y, Yoshioka T, Kishi Y, Iwamoto M, Nakamura M, Sando Y, Yagita H, Koreth J, Kim HT, et al. PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy. Blood. 2017;129:2186\u201397.","journal-title":"Blood"},{"key":"742_CR9","doi-asserted-by":"publisher","first-page":"63","DOI":"10.4062\/biomolther.2018.201","volume":"27","author":"S Nam","year":"2019","unstructured":"Nam S, Lee A, Lim J, Lim JS. Analysis of the expression and regulation of PD-1 protein on the surface of myeloid-derived suppressor cells (MDSCs). Biomol Ther (Seoul). 2019;27:63\u201370.","journal-title":"Biomol Ther (Seoul)"},{"key":"742_CR10","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.kint.2020.05.013","volume":"98","author":"M Noris","year":"2020","unstructured":"Noris M, Benigni A, Remuzzi G. The case of complement activation in COVID-19 multiorgan impact. Kidney Int. 2020;98:314\u201322.","journal-title":"Kidney Int"},{"key":"742_CR11","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.3390\/cells8091083","volume":"8","author":"MZ Noman","year":"2019","unstructured":"Noman MZ, Hasmim M, Lequeux A, Xiao M, Duhem C, Chouaib S, Berchem G, Janji B. Improving cancer immunotherapy by targeting the hypoxic tumor microenvironment: new opportunities and challenges. Cells-Basel. 2019;8:1083.","journal-title":"Cells-Basel"},{"key":"742_CR12","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1080\/15476286.2019.1649585","volume":"16","author":"ZL Ou","year":"2019","unstructured":"Ou ZL, Luo Z, Wei W, Liang S, Gao TL, Lu YB. Hypoxia-induced shedding of MICA and HIF1A-mediated immune escape of pancreatic cancer cells from NK cells: role of circ_0000977\/miR-153 axis. Rna Biol. 2019;16:1592\u2013603.","journal-title":"Rna Biol"},{"key":"742_CR13","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1038\/s41416-020-0985-5","volume":"123","author":"SG Craig","year":"2020","unstructured":"Craig SG, Humphries MP, Alderdice M, Bingham V, Richman SD, Loughrey MB, Coleman HG, Viratham-Pulsawatdi A, McCombe K, Murray GI, et al. Immune status is prognostic for poor survival in colorectal cancer patients and is associated with tumour hypoxia. Br J Cancer. 2020;123:1280\u20138.","journal-title":"Br J Cancer"},{"key":"742_CR14","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1177\/0271678X18813317","volume":"40","author":"T Yan","year":"2018","unstructured":"Yan T, Chen Z, Chopp M, Venkat P, Zacharek A, Li W, Shen Y, Wu R, Li L, Landschoot-Ward J, et al. Inflammatory responses mediate brain-heart interaction after ischemic stroke in adult mice. J Cereb Blood Flow Metab. 2018;40:1213\u201329.","journal-title":"J Cereb Blood Flow Metab"},{"key":"742_CR15","doi-asserted-by":"publisher","first-page":"6523","DOI":"10.4049\/jimmunol.176.11.6523","volume":"176","author":"H Offner","year":"2006","unstructured":"Offner H, Subramanian S, Parker SM, Wang C, Afentoulis ME, Lewis A, Vandenbark AA, Hurn PD. Splenic atrophy in experimental stroke is accompanied by increased regulatory T cells and circulating macrophages. J Immunol. 2006;176:6523\u201331.","journal-title":"J Immunol"},{"key":"742_CR16","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1196\/annals.1361.076","volume":"1051","author":"L Dyugovskaya","year":"2005","unstructured":"Dyugovskaya L, Lavie P, Lavie L. Lymphocyte activation as a possible measure of atherosclerotic risk in patients with sleep apnea. Ann N Y Acad Sci. 2005;1051:340\u201350.","journal-title":"Ann N Y Acad Sci"},{"key":"742_CR17","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1164\/rccm.201012-2033OC","volume":"184","author":"C Arnaud","year":"2011","unstructured":"Arnaud C, Beguin PC, Lantuejoul S, Pepin JL, Guillermet C, Pelli G, Burger F, Buatois V, Ribuot C, Baguet JP, et al. The inflammatory preatherosclerotic remodeling induced by intermittent hypoxia is attenuated by RANTES\/CCL5 inhibition. Am J Respir Crit Care Med. 2011;184:724\u201331.","journal-title":"Am J Respir Crit Care Med"},{"key":"742_CR18","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1183\/09031936.05.00103204","volume":"25","author":"L Dyugovskaya","year":"2005","unstructured":"Dyugovskaya L, Lavie P, Hirsh M, Lavie L. Activated CD8+ T-lymphocytes in obstructive sleep apnoea. Eur Respir J. 2005;25:820\u20138.","journal-title":"Eur Respir J"},{"key":"742_CR19","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1164\/rccm.200210-1226OC","volume":"168","author":"L Dyugovskaya","year":"2003","unstructured":"Dyugovskaya L, Lavie P, Lavie L. Phenotypic and functional characterization of blood gammadelta T cells in sleep apnea. Am J Respir Crit Care Med. 2003;168:242\u20139.","journal-title":"Am J Respir Crit Care Med"},{"key":"742_CR20","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.mam.2015.12.004","volume":"47\u201348","author":"EP Cummins","year":"2016","unstructured":"Cummins EP, Keogh CE, Crean D, Taylor CT. The role of HIF in immunity and inflammation. Mol Aspects Med. 2016;47\u201348:24\u201334.","journal-title":"Mol Aspects Med"},{"key":"742_CR21","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.cmet.2020.08.002","volume":"32","author":"AF McGettrick","year":"2020","unstructured":"McGettrick AF, O\u2019Neill L. The role of HIF in immunity and inflammation. Cell Metab. 2020;32:524\u201336.","journal-title":"Cell Metab"},{"key":"742_CR22","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/nri.2016.70","volume":"16","author":"LA O'Neill","year":"2016","unstructured":"O\u2019Neill LA, Kishton RJ, Rathmell J. A guide to immunometabolism for immunologists. Nat Rev Immunol. 2016;16:553\u201365.","journal-title":"Nat Rev Immunol"},{"key":"742_CR23","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/nature11986","volume":"496","author":"GM Tannahill","year":"2013","unstructured":"Tannahill GM, Curtis AM, Adamik J, Palsson-McDermott EM, McGettrick AF, Goel G, Frezza C, Bernard NJ, Kelly B, Foley NH, et al. Succinate is an inflammatory signal that induces IL-1beta through HIF-1alpha. Nature. 2013;496:238\u201342.","journal-title":"Nature"},{"key":"742_CR24","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.cell.2011.07.033","volume":"146","author":"EV Dang","year":"2011","unstructured":"Dang EV, Barbi J, Yang HY, Jinasena D, Yu H, Zheng Y, Bordman Z, Fu J, Kim Y, Yen HR, et al. Control of T(H)17\/T(reg) balance by hypoxia-inducible factor 1. Cell. 2011;146:772\u201384.","journal-title":"Cell"},{"key":"742_CR25","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12943-018-0869-y","volume":"17","author":"C Shao","year":"2018","unstructured":"Shao C, Yang F, Miao S, Liu W, Wang C, Shu Y, Shen H. Role of hypoxia-induced exosomes in tumor biology. Mol Cancer. 2018;17:120.","journal-title":"Mol Cancer"},{"key":"742_CR26","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1084\/jem.20011624","volume":"195","author":"G Andreola","year":"2002","unstructured":"Andreola G, Rivoltini L, Castelli C, Huber V, Perego P, Deho P, Squarcina P, Accornero P, Lozupone F, Lugini L, et al. Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J Exp Med. 2002;195:1303\u201316.","journal-title":"J Exp Med"},{"key":"742_CR27","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/path.4781","volume":"240","author":"SB Ye","year":"2016","unstructured":"Ye SB, Zhang H, Cai TT, Liu YN, Ni JJ, He J, Peng JY, Chen QY, Mo HY, et al. Exosomal miR-24-3p impedes T-cell function by targeting FGF11 and serves as a potential prognostic biomarker for nasopharyngeal carcinoma. J Pathol. 2016;240:329\u201340.","journal-title":"J Pathol"},{"key":"742_CR28","doi-asserted-by":"publisher","first-page":"105704","DOI":"10.1016\/j.intimp.2019.105704","volume":"74","author":"M Wu","year":"2019","unstructured":"Wu M, Liu F, Guo Q. Quercetin attenuates hypoxia-ischemia induced brain injury in neonatal rats by inhibiting TLR4\/NF-kappaB signaling pathway. Int Immunopharmacol. 2019;74:105704.","journal-title":"Int Immunopharmacol"},{"key":"742_CR29","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s40478-019-0747-x","volume":"7","author":"SW Kim","year":"2019","unstructured":"Kim SW, Lee H, Lee HK, Kim ID, Lee JK. Neutrophil extracellular trap induced by HMGB1 exacerbates damages in the ischemic brain. Acta Neuropathol Commun. 2019;7:94.","journal-title":"Acta Neuropathol Commun"},{"key":"742_CR30","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1084\/jem.20131916","volume":"211","author":"MZ Noman","year":"2014","unstructured":"Noman MZ, Desantis G, Janji B, Hasmim M, Karray S, Dessen P, Bronte V, Chouaib S. PD-L1 is a novel direct target of HIF-1alpha, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med. 2014;211:781\u201390.","journal-title":"J Exp Med"},{"key":"742_CR31","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1161\/STROKEAHA.111.613182","volume":"42","author":"X Ren","year":"2011","unstructured":"Ren X, Akiyoshi K, Vandenbark AA, Hurn PD, Offner H. Programmed death-1 pathway limits central nervous system inflammation and neurologic deficits in murine experimental stroke. Stroke. 2011;42:2578\u201383.","journal-title":"Stroke"},{"key":"742_CR32","doi-asserted-by":"publisher","first-page":"1700833","DOI":"10.1183\/13993003.00833-2017","volume":"50","author":"C Cubillos-Zapata","year":"2017","unstructured":"Cubillos-Zapata C, Avendano-Ortiz J, Hernandez-Jimenez E, Toledano V, Casas-Martin J, Varela-Serrano A, Torres M, Almendros I, Casitas R, Fernandez-Navarro I, et al. Hypoxia-induced PD-L1\/PD-1 crosstalk impairs T-cell function in sleep apnoea. Eur Respir J. 2017;50:1700833.","journal-title":"Eur Respir J"},{"key":"742_CR33","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1111\/resp.13470","volume":"24","author":"C Cubillos-Zapata","year":"2019","unstructured":"Cubillos-Zapata C, Balbas-Garcia C, Avendano-Ortiz J, Toledano V, Torres M, Almendros I, Casitas R, Zamarron E, Garcia-Sanchez A, Feliu J, et al. Age-dependent hypoxia-induced PD-L1 upregulation in patients with obstructive sleep apnoea. Respirology. 2019;24:684\u201392.","journal-title":"Respirology"},{"key":"742_CR34","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.jvir.2020.03.023","volume":"31","author":"H Takaki","year":"2020","unstructured":"Takaki H, Hirata Y, Ueshima E, Kodama H, Matsumoto S, Wada R, Suzuki H, Nakasho K, Yamakado K. Hepatic artery embolization enhances expression of programmed cell death 1 ligand 1 in an orthotopic rat hepatocellular carcinoma model. in vivo and in vitro experimentation. J Vasc Interv Radiol. 2020;31:1475\u201382.","journal-title":"J Vasc Interv Radiol"},{"key":"742_CR35","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.phrs.2018.08.004","volume":"135","author":"Y Xing","year":"2018","unstructured":"Xing Y, Mi C, Wang Z, Zhang ZH, Li MY, Zuo HX, Wang JY, Jin X, Ma J. Fraxinellone has anticancer activity in vivo by inhibiting programmed cell death-ligand 1 expression by reducing hypoxia-inducible factor-1alpha and STAT3. Pharmacol Res. 2018;135:166\u201380.","journal-title":"Pharmacol Res"},{"key":"742_CR36","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1093\/infdis\/jix279","volume":"217","author":"J Avendano-Ortiz","year":"2018","unstructured":"Avendano-Ortiz J, Maroun-Eid C, Martin-Quiros A, Toledano V, Cubillos-Zapata C, Gomez-Campelo P, Varela-Serrano A, Casas-Martin J, Llanos-Gonzalez E, Alvarez E, et al. PD-L1 overexpression during endotoxin tolerance impairs the adaptive immune response in septic patients via HIF1alpha. J Infect Dis. 2018;217:393\u2013404.","journal-title":"J Infect Dis"},{"key":"742_CR37","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12964-019-0391-x","volume":"17","author":"C Vincent-Fabert","year":"2019","unstructured":"Vincent-Fabert C, Roland L, Zimber-Strobl U, Feuillard J, Faumont N. Pre-clinical blocking of PD-L1 molecule, which expression is down regulated by NF-kappaB, JAK1\/JAK2 and BTK inhibitors, induces regression of activated B-cell lymphoma. Cell Commun Signal. 2019;17:89.","journal-title":"Cell Commun Signal"},{"key":"742_CR38","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1038\/bjc.2015.101","volume":"112","author":"K Abiko","year":"2015","unstructured":"Abiko K, Matsumura N, Hamanishi J, Horikawa N, Murakami R, Yamaguchi K, Yoshioka Y, Baba T, Konishi I, Mandai M. IFN-gamma from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. Br J Cancer. 2015;112:1501\u20139.","journal-title":"Br J Cancer"},{"key":"742_CR39","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","volume":"192","author":"GJ Freeman","year":"2000","unstructured":"Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192:1027\u201334.","journal-title":"J Exp Med"},{"key":"742_CR40","doi-asserted-by":"publisher","first-page":"e1423170","DOI":"10.1080\/2162402X.2017.1423170","volume":"7","author":"A Asgarova","year":"2018","unstructured":"Asgarova A, Asgarov K, Godet Y, Peixoto P, Nadaradjane A, Boyer-Guittaut M, Galaine J, Guenat D, Mougey V, Perrard J, et al. PD-L1 expression is regulated by both DNA methylation and NF-kB during EMT signaling in non-small cell lung carcinoma. Oncoimmunology. 2018;7:e1423170.","journal-title":"Oncoimmunology"},{"key":"742_CR41","doi-asserted-by":"publisher","first-page":"16824","DOI":"10.1002\/jcp.28358","volume":"234","author":"A Salmaninejad","year":"2019","unstructured":"Salmaninejad A, Valilou SF, Shabgah AG, Aslani S, Alimardani M, Pasdar A, Sahebkar A. PD-1\/PD-L1 pathway: basic biology and role in cancer immunotherapy. J Cell Physiol. 2019;234:16824\u201337.","journal-title":"J Cell Physiol"},{"key":"742_CR42","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12943-019-1074-3","volume":"18","author":"F Xie","year":"2019","unstructured":"Xie F, Xu M, Lu J, Mao L, Wang S. The role of exosomal PD-L1 in tumor progression and immunotherapy. Mol Cancer. 2019;18:146.","journal-title":"Mol Cancer"},{"key":"742_CR43","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/s41586-018-0392-8","volume":"560","author":"G Chen","year":"2018","unstructured":"Chen G, Huang AC, Zhang W, Zhang G, Wu M, Xu W, Yu Z, Yang J, Wang B, Sun H, et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature. 2018;560:382\u20136.","journal-title":"Nature"},{"key":"742_CR44","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1038\/s41388-018-0627-z","volume":"38","author":"L Li","year":"2019","unstructured":"Li L, Cao B, Liang X, Lu S, Luo H, Wang Z, Wang S, Jiang J, Lang J, Zhu G. Microenvironmental oxygen pressure orchestrates an anti- and pro-tumoral gammadelta T cell equilibrium via tumor-derived exosomes. Oncogene. 2019;38:2830\u201343.","journal-title":"Oncogene"},{"key":"742_CR45","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1084\/jem.20090847","volume":"206","author":"LM Francisco","year":"2009","unstructured":"Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, Sharpe AH. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med. 2009;206:3015\u201329.","journal-title":"J Exp Med"},{"key":"742_CR46","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1158\/2326-6066.CIR-18-0062","volume":"6","author":"F Concha-Benavente","year":"2018","unstructured":"Concha-Benavente F, Kansy B, Moskovitz J, Moy J, Chandran U, Ferris RL. PD-L1 mediates dysfunction in activated PD-1(+) NK cells in head and neck cancer patients. Cancer Immunol Res. 2018;6:1548\u201360.","journal-title":"Cancer Immunol Res"},{"key":"742_CR47","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.coi.2011.12.009","volume":"24","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1\/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol. 2012;24:207\u201312.","journal-title":"Curr Opin Immunol"},{"key":"742_CR48","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1084\/jem.20112741","volume":"209","author":"T Yokosuka","year":"2012","unstructured":"Yokosuka T, Takamatsu M, Kobayashi-Imanishi W, Hashimoto-Tane A, Azuma M, Saito T. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J Exp Med. 2012;209:1201\u201317.","journal-title":"J Exp Med"},{"key":"742_CR49","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1126\/science.aaf1292","volume":"355","author":"E Hui","year":"2017","unstructured":"Hui E, Cheung J, Zhu J, Su X, Taylor MJ, Wallweber HA, Sasmal DK, Huang J, Kim JM, Mellman I, Vale RD. T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. Science. 2017;355:1428\u201333.","journal-title":"Science"},{"key":"742_CR50","doi-asserted-by":"publisher","first-page":"711","DOI":"10.4049\/jimmunol.170.2.711","volume":"170","author":"F Bennett","year":"2003","unstructured":"Bennett F, Luxenberg D, Ling V, Wang IM, Marquette K, Lowe D, Khan N, Veldman G, Jacobs KA, Valge-Archer VE, et al. Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses. J Immunol. 2003;170:711\u20138.","journal-title":"J Immunol"},{"key":"742_CR51","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1038\/ni.1790","volume":"10","author":"BT Fife","year":"2009","unstructured":"Fife BT, Pauken KE, Eagar TN, Obu T, Wu J, Tang Q, Azuma M, Krummel MF, Bluestone JA. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol. 2009;10:1185\u201392.","journal-title":"Nat Immunol"},{"key":"742_CR52","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.febslet.2004.07.083","volume":"574","author":"KA Sheppard","year":"2004","unstructured":"Sheppard KA, Fitz LJ, Lee JM, Benander C, George JA, Wooters J, Qiu Y, Jussif JM, Carter LL, Wood CR, Chaudhary D. PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70\/CD3zeta signalosome and downstream signaling to PKCtheta. Febs Lett. 2004;574:37\u201341.","journal-title":"Febs Lett"},{"key":"742_CR53","doi-asserted-by":"publisher","first-page":"6692","DOI":"10.1038\/ncomms7692","volume":"6","author":"N Patsoukis","year":"2015","unstructured":"Patsoukis N, Bardhan K, Chatterjee P, Sari D, Liu B, Bell LN, Karoly ED, Freeman GJ, Petkova V, Seth P, et al. PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat Commun. 2015;6:6692.","journal-title":"Nat Commun"},{"key":"742_CR54","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1002\/1521-4141(200203)32:3<634::AID-IMMU634>3.0.CO;2-9","volume":"32","author":"L Carter","year":"2002","unstructured":"Carter L, Fouser LA, Jussif J, Fitz L, Deng B, Wood CR, Collins M, Honjo T, Freeman GJ, Carreno BM. PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2. Eur J Immunol. 2002;32:634\u201343.","journal-title":"Eur J Immunol"},{"key":"742_CR55","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1161\/STROKEAHA.113.004100","volume":"45","author":"P Li","year":"2014","unstructured":"Li P, Mao L, Liu X, Gan Y, Zheng J, Thomson AW, Gao Y, Chen J, Hu X. Essential role of program death 1-ligand 1 in regulatory T-cell-afforded protection against blood-brain barrier damage after stroke. Stroke. 2014;45:857\u201364.","journal-title":"Stroke"},{"key":"742_CR56","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1182\/blood-2010-03-275446","volume":"116","author":"Q Zhou","year":"2010","unstructured":"Zhou Q, Munger ME, Highfill SL, Tolar J, Weigel BJ, Riddle M, Sharpe AH, Vallera DA, Azuma M, Levine BL, et al. Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia. Blood. 2010;116:2484\u201393.","journal-title":"Blood"},{"key":"742_CR57","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jaci.2016.04.025","volume":"139","author":"S Pesce","year":"2017","unstructured":"Pesce S, Greppi M, Tabellini G, Rampinelli F, Parolini S, Olive D, Moretta L, Moretta A, Marcenaro E. Identification of a subset of human natural killer cells expressing high levels of programmed death 1: a phenotypic and functional characterization. J Allergy Clin Immunol. 2017;139:335\u201346.","journal-title":"J Allergy Clin Immunol"},{"key":"742_CR58","doi-asserted-by":"publisher","first-page":"4654","DOI":"10.1172\/JCI99317","volume":"128","author":"J Hsu","year":"2018","unstructured":"Hsu J, Hodgins JJ, Marathe M, Nicolai CJ, Bourgeois-Daigneault MC, Trevino TN, Azimi CS, Scheer AK, Randolph HE, Thompson TW, et al. Contribution of NK cells to immunotherapy mediated by PD-1\/PD-L1 blockade. J Clin Invest. 2018;128:4654\u201368.","journal-title":"J Clin Invest"},{"key":"742_CR59","doi-asserted-by":"publisher","first-page":"e1509819","DOI":"10.1080\/2162402X.2018.1509819","volume":"7","author":"JL Oyer","year":"2018","unstructured":"Oyer JL, Gitto SB, Altomare DA, Copik AJ. PD-L1 blockade enhances anti-tumor efficacy of NK cells. Oncoimmunology. 2018;7:e1509819.","journal-title":"Oncoimmunology"},{"key":"742_CR60","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1084\/jem.20122571","volume":"210","author":"G Gasteiger","year":"2013","unstructured":"Gasteiger G, Hemmers S, Bos PD, Sun JC, Rudensky AY. IL-2-dependent adaptive control of NK cell homeostasis. J Exp Med. 2013;210:1179\u201387.","journal-title":"J Exp Med"},{"key":"742_CR61","doi-asserted-by":"publisher","first-page":"e000873","DOI":"10.1136\/jitc-2020-000873","volume":"8","author":"JE Park","year":"2020","unstructured":"Park JE, Kim SE, Keam B, Park HR, Kim S, Kim M, Kim TM, Doh J, Kim DW, Heo DS. Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines. J Immunother Cancer. 2020;8:e000873.","journal-title":"J Immunother Cancer"},{"key":"742_CR62","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1158\/2159-8290.CD-18-1259","volume":"9","author":"W Dong","year":"2019","unstructured":"Dong W, Wu X, Ma S, Wang Y, Nalin AP, Zhu Z, Zhang J, Benson DM, He K, Caligiuri MA, Yu J. The mechanism of anti-PD-L1 antibody efficacy against PD-L1-negative tumors identifies NK cells expressing PD-L1 as a cytolytic effector. Cancer Discov. 2019;9:1422\u201337.","journal-title":"Cancer Discov"},{"key":"742_CR63","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nrc704","volume":"2","author":"AL Harris","year":"2002","unstructured":"Harris AL. Hypoxia\u2013a key regulatory factor in tumour growth. Nat Rev Cancer. 2002;2:38\u201347.","journal-title":"Nat Rev Cancer"},{"key":"742_CR64","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","volume":"26","author":"ME Keir","year":"2008","unstructured":"Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677\u2013704.","journal-title":"Annu Rev Immunol"},{"key":"742_CR65","doi-asserted-by":"publisher","first-page":"153425","DOI":"10.1016\/j.phymed.2020.153425","volume":"81","author":"YF Zhang","year":"2021","unstructured":"Zhang YF, Zhang ZH, Li MY, Wang JY, Xing Y, Ri M, Jin CH, Xu GH, Piao LX, Zuo HX, et al. Britannin stabilizes T cell activity and inhibits proliferation and angiogenesis by targeting PD-L1 via abrogation of the crosstalk between Myc and HIF-1alpha in cancer. Phytomedicine. 2021;81:153425.","journal-title":"Phytomedicine"},{"key":"742_CR66","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1093\/intimm\/dxp072","volume":"21","author":"W Wang","year":"2009","unstructured":"Wang W, Lau R, Yu D, Zhu W, Korman A, Weber J. PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells. Int Immunol. 2009;21:1065\u201377.","journal-title":"Int Immunol"},{"key":"742_CR67","doi-asserted-by":"publisher","first-page":"6964","DOI":"10.1158\/0008-5472.CAN-16-0258","volume":"76","author":"CA Clark","year":"2016","unstructured":"Clark CA, Gupta HB, Sareddy G, Pandeswara S, Lao S, Yuan B, Drerup JM, Padron A, Conejo-Garcia J, Murthy K, et al. Tumor-intrinsic PD-L1 signals regulate cell growth, pathogenesis, and autophagy in ovarian cancer and melanoma. Cancer Res. 2016;76:6964\u201374.","journal-title":"Cancer Res"},{"key":"742_CR68","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2015","unstructured":"Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma. N Engl J Med. 2015;372:311\u20139.","journal-title":"N Engl J Med"},{"key":"742_CR69","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443\u201354.","journal-title":"N Engl J Med"},{"key":"742_CR70","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455\u201365.","journal-title":"N Engl J Med"},{"key":"742_CR71","doi-asserted-by":"publisher","first-page":"6023","DOI":"10.2147\/OTT.S214579","volume":"12","author":"R Jiao","year":"2019","unstructured":"Jiao R, Luo H, Xu W, Ge H. Immune checkpoint inhibitors in esophageal squamous cell carcinoma: progress and opportunities. Onco Targets Ther. 2019;12:6023\u201332.","journal-title":"Onco Targets Ther"},{"key":"742_CR72","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.2147\/IJN.S225807","volume":"15","author":"Y Hei","year":"2020","unstructured":"Hei Y, Teng B, Zeng Z, Zhang S, Li Q, Pan J, Luo Z, Xiong C, Wei S. Multifunctional immunoliposomes combining catalase and PD-L1 antibodies overcome tumor hypoxia and enhance immunotherapeutic effects against melanoma. Int J Nanomed. 2020;15:1677\u201391.","journal-title":"Int J Nanomed"},{"key":"742_CR73","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.molmed.2014.10.009","volume":"21","author":"KC Ohaegbulam","year":"2015","unstructured":"Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med. 2015;21:24\u201333.","journal-title":"Trends Mol Med"},{"key":"742_CR74","first-page":"129","volume":"35","author":"Y Shindo","year":"2015","unstructured":"Shindo Y, Yoshimura K, Kuramasu A, Watanabe Y, Ito H, Kondo T, Oga A, Ito H, Yoshino S, Hazama S, et al. Combination immunotherapy with 4\u20131BB activation and PD-1 blockade enhances antitumor efficacy in a mouse model of subcutaneous tumor. Anticancer Res. 2015;35:129\u201336.","journal-title":"Anticancer Res"},{"key":"742_CR75","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1016\/j.jtho.2019.08.2503","volume":"14","author":"A Gagne","year":"2019","unstructured":"Gagne A, Wang E, Bastien N, Orain M, Desmeules P, Page S, Trahan S, Couture C, Joubert D, Joubert P. Impact of specimen characteristics on PD-L1 testing in non-small cell lung cancer: validation of the IASLC PD-L1 testing guidelines. J Thorac Oncol. 2019;14:2062\u201370.","journal-title":"J Thorac Oncol"},{"key":"742_CR76","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.lungcan.2019.09.013","volume":"137","author":"K Teramoto","year":"2019","unstructured":"Teramoto K, Igarashi T, Kataoka Y, Ishida M, Hanaoka J, Sumimoto H, Daigo Y. Clinical significance of PD-L1-positive cancer-associated fibroblasts in pN0M0 non-small cell lung cancer. Lung Cancer. 2019;137:56\u201363.","journal-title":"Lung Cancer"},{"key":"742_CR77","doi-asserted-by":"publisher","first-page":"429","DOI":"10.21037\/tlcr.2019.08.04","volume":"8","author":"H Li","year":"2019","unstructured":"Li H, Xu Y, Wan B, Song Y, Zhan P, Hu Y, Zhang Q, Zhang F, Liu H, Li T, et al. The clinicopathological and prognostic significance of PD-L1 expression assessed by immunohistochemistry in lung cancer: a meta-analysis of 50 studies with 11,383 patients. Transl Lung Cancer Res. 2019;8:429\u201349.","journal-title":"Transl Lung Cancer Res"},{"key":"742_CR78","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1002\/glia.22701","volume":"62","author":"SJ Schachtele","year":"2014","unstructured":"Schachtele SJ, Hu S, Sheng WS, Mutnal MB, Lokensgard JR. Glial cells suppress postencephalitic CD8+ T lymphocytes through PD-L1. Glia. 2014;62:1582\u201394.","journal-title":"Glia"},{"key":"742_CR79","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1161\/STROKEAHA.117.016705","volume":"48","author":"R Han","year":"2017","unstructured":"Han R, Luo J, Shi Y, Yao Y, Hao J. PD-L1 (Programmed Death Ligand 1) Protects against experimental intracerebral hemorrhage-induced brain injury. Stroke. 2017;48:2255\u201362.","journal-title":"Stroke"},{"key":"742_CR80","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/1742-2094-10-111","volume":"10","author":"S Bodhankar","year":"2013","unstructured":"Bodhankar S, Chen Y, Vandenbark AA, Murphy SJ, Offner H. PD-L1 enhances CNS inflammation and infarct volume following experimental stroke in mice in opposition to PD-1. J Neuroinflammation. 2013;10:111.","journal-title":"J Neuroinflammation"},{"key":"742_CR81","doi-asserted-by":"publisher","first-page":"zsz285","DOI":"10.1093\/sleep\/zsz285","volume":"43","author":"C Cubillos-Zapata","year":"2020","unstructured":"Cubillos-Zapata C, Almendros I, Diaz-Garcia E, Toledano V, Casitas R, Galera R, Lopez-Collazo E, Farre R, Gozal D, Garcia-Rio F. Differential effect of intermittent hypoxia and sleep fragmentation on PD-1\/PD-L1 upregulation. Sleep. 2020;43:zsz285.","journal-title":"Sleep"},{"key":"742_CR82","doi-asserted-by":"publisher","first-page":"1801298","DOI":"10.1183\/13993003.01298-2018","volume":"53","author":"C Cubillos-Zapata","year":"2019","unstructured":"Cubillos-Zapata C, Martinez-Garcia MA, Campos-Rodriguez F, Sanchez DLTM, Nagore E, Martorell-Calatayud A, Hernandez BL, Chiner VE, Abad-Capa J, Montserrat JM, et al. Soluble PD-L1 is a potential biomarker of cutaneous melanoma aggressiveness and metastasis in obstructive sleep apnoea patients. Eur Respir J. 2019;53:1801298.","journal-title":"Eur Respir J"},{"key":"742_CR83","doi-asserted-by":"publisher","first-page":"97","DOI":"10.21037\/atm.2019.01.44","volume":"7","author":"MH Huang","year":"2019","unstructured":"Huang MH, Zhang XB, Wang HL, Li LX, Zeng YM, Wang M, Zeng HQ. Intermittent hypoxia enhances the tumor programmed death ligand 1 expression in a mouse model of sleep apnea. Ann Transl Med. 2019;7:97.","journal-title":"Ann Transl Med"},{"key":"742_CR84","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1681\/ASN.2008111160","volume":"20","author":"GR Kinsey","year":"2009","unstructured":"Kinsey GR, Sharma R, Huang L, Li L, Vergis AL, Ye H, Ju ST, Okusa MD. Regulatory T cells suppress innate immunity in kidney ischemia-reperfusion injury. J Am Soc Nephrol. 2009;20:1744\u201353.","journal-title":"J Am Soc Nephrol"},{"key":"742_CR85","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/ki.2009.259","volume":"76","author":"MT Gandolfo","year":"2009","unstructured":"Gandolfo MT, Jang HR, Bagnasco SM, Ko GJ, Agreda P, Satpute SR, Crow MT, King LS, Rabb H. Foxp3+ regulatory T cells participate in repair of ischemic acute kidney injury. Kidney Int. 2009;76:717\u201329.","journal-title":"Kidney Int"},{"key":"742_CR86","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1681\/ASN.2012080784","volume":"24","author":"MG Kim","year":"2013","unstructured":"Kim MG, Koo TY, Yan JJ, Lee E, Han KH, Jeong JC, Ro H, Kim BS, Jo SK, Oh KH, et al. IL-2\/anti-IL-2 complex attenuates renal ischemia-reperfusion injury through expansion of regulatory T cells. J Am Soc Nephrol. 2013;24:1529\u201336.","journal-title":"J Am Soc Nephrol"},{"key":"742_CR87","doi-asserted-by":"publisher","first-page":"325","DOI":"10.4049\/jimmunol.1400497","volume":"194","author":"K Jaworska","year":"2015","unstructured":"Jaworska K, Ratajczak J, Huang L, Whalen K, Yang M, Stevens BK, Kinsey GR. Both PD-1 ligands protect the kidney from ischemia reperfusion injury. J Immunol. 2015;194:325\u201333.","journal-title":"J Immunol"},{"key":"742_CR88","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1681\/ASN.2012010070","volume":"23","author":"GR Kinsey","year":"2012","unstructured":"Kinsey GR, Huang L, Jaworska K, Khutsishvili K, Becker DA, Ye H, Lobo PI, Okusa MD. Autocrine adenosine signaling promotes regulatory T cell-mediated renal protection. J Am Soc Nephrol. 2012;23:1528\u201337.","journal-title":"J Am Soc Nephrol"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-021-00742-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-021-00742-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-021-00742-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T21:15:50Z","timestamp":1634159750000},"score":1,"resource":{"primary":{"URL":"https:\/\/biosignaling.biomedcentral.com\/articles\/10.1186\/s12964-021-00742-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,13]]},"references-count":88,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["742"],"URL":"https:\/\/doi.org\/10.1186\/s12964-021-00742-x","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.21203\/rs.3.rs-966262\/v1","asserted-by":"subject"}]},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,13]]},"assertion":[{"value":"8 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"76"}}